cas 2149584-03-0|| where to buy Phe-Lys(Fmoc)-PAB

Nombre del producto:Phe-Lys(Fmoc)-PAB

IUPAC Name:(9H-fluoren-9-yl)methyl N-[(5S)-5-[(2S)-2-amino-3-phenylpropanamido]-5-{[4-(hydroxymethyl)phenyl]carbamoyl}pentyl]carbamate

Unidad de embalaje	Stock disponible	Precio($)	Cantidad
CM339216-100mg	in stock	œœȋ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2149584-03-0 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :2149584-03-0; Fórmula molecular:C37H40N4O5; Punto de fusión:-; Código de sonrisas:OCC(C=C1)=CC=C1NC([C@@H](NC([C@@H](N)CC2=CC=CC=C2)=O)CCCCNC(OCC3C4=CC=CC=C4C5=CC=CC=C35)=O)=O; Densidad:

: Número de catálogo:CM339216; Peso molecular:620.75; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: ADC-Linkers; The ADC linker is one of the three main components of antibody drug conjugates (ADCs), linking the antibody to the effective drug (payload) through chemical bonds. ADC linkers play a key role in determining the overall success of antibody drug conjugates. One of the major challenges in developing safe and effective ADC drugs is to assemble an ideal chemical linker between the cytotoxic payload and the mAb. Well-designed ADC linkers can help the selective delivery of antibodies at the tumor site and the accurate release of cytotoxic drugs.

: Cleavable linkers; Cleavable linkers rely on the inherent properties of a cell’s cytoplasmic compartments for selective release of the cytotoxic drug.

: Peptide linkers; Peptide linkers belong to protease-sensitivity linkers (also called enzymatically cleavable linkers) that have gained significant attention in ADC development due to their superior plasma stability and controled payload release mechanism.